← Back to Clinical Trials
Recruiting Phase 4 NCT05856136

NCT05856136 A Study to Investigate of the Effects of Opioid Exposure on the Ability of the Diaphragm Muscle

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05856136
Status Recruiting
Phase Phase 4
Sponsor Mayo Clinic
Condition Respiratory Function Loss
Study Type INTERVENTIONAL
Enrollment 69 participants
Start Date 2023-06-19
Primary Completion 2025-12-08

Trial Parameters

Condition Respiratory Function Loss
Sponsor Mayo Clinic
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 69
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-06-19
Completion 2025-12-08
Interventions
Fentanyl Injection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to evaluate opioid dose effects on the ability of the diaphragm muscle to generate higher force behaviors.

Eligibility Criteria

Inclusion Criteria: \- Adult male and female patients undergoing lower extremity orthopedic surgery at the study institutions (St. Mary Hospital and Rochester Methodist Hospital within the Mayo Clinic Rochester hospital system). Exclusion Criteria: * Patients who refuse research participation. * Patients who are pregnant. * Patients with known pulmonary pathology (COPD, asthma requiring routine treatment).

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE RESPIRATORY FUNCTION LOSS TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology